,0
zip,19803
sector,Healthcare
fullTimeEmployees,1773
longBusinessSummary,"Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naÃ¯ve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware."
city,Wilmington
phone,302 498 6700
state,DE
country,United States
companyOfficers,[]
website,https://www.incyte.com
maxAge,1
address1,1801 Augustine Cut-Off
industry,Biotechnology
ebitdaMargins,0.24486999
profitMargins,0.18351999
grossMargins,0.45874
operatingCashflow,741457984
revenueGrowth,0.31
operatingMargins,0.22474001
ebitda,713297984
targetLowPrice,66
recommendationKey,buy
grossProfits,276631000
freeCashflow,387478752
targetMedianPrice,92.5
currentPrice,78.46
earningsGrowth,
currentRatio,3.937
returnOnAssets,0.10902
numberOfAnalystOpinions,16
targetMeanPrice,92.25
debtToEquity,1.86
returnOnEquity,0.19301
targetHighPrice,136
totalCash,2284075008
totalDebt,58576000
totalRevenue,2912922880
totalCashPerShare,10.34
financialCurrency,USD
revenuePerShare,13.241
quickRatio,3.771
recommendationMean,2.1
exchange,NMS
shortName,Incyte Corporation
longName,Incyte Corporation
exchangeTimezoneName,America/New_York
exchangeTimezoneShortName,EDT
isEsgPopulated,True
gmtOffSetMilliseconds,-14400000
underlyingSymbol,
quoteType,EQUITY
symbol,INCY
underlyingExchangeSymbol,
headSymbol,
messageBoardId,finmb_332954
uuid,72960770-e83b-3ec3-92c6-dbd8ced339a4
market,us_market
annualHoldingsTurnover,
enterpriseToRevenue,4.681
beta3Year,
enterpriseToEbitda,19.118
52WeekChange,
morningStarRiskRating,
forwardEps,4.38
revenueQuarterlyGrowth,
sharesOutstanding,220891008
fundInceptionDate,
annualReportExpenseRatio,
totalAssets,
bookValue,14.255
sharesShort,4561847
sharesPercentSharesOut,0.0207
fundFamily,
lastFiscalYearEnd,1609372800
heldPercentInstitutions,0.93845004
netIncomeToCommon,534580000
trailingEps,2.412
lastDividendValue,
SandP52WeekChange,
priceToBook,5.5040336
heldPercentInsiders,0.01513
nextFiscalYearEnd,1672444800
yield,
mostRecentQuarter,1632960000
shortRatio,1.92
sharesShortPreviousMonthDate,1636934400
floatShares,185625431
beta,0.71948
enterpriseValue,13636656128
priceHint,2
threeYearAverageReturn,
lastSplitDate,967766400
lastSplitFactor,2:1
legalType,
morningStarOverallRating,
earningsQuarterlyGrowth,
priceToSalesTrailing12Months,5.949731
dateShortInterest,1639526400
pegRatio,1.37
ytdReturn,
forwardPE,17.91324
lastCapGain,
shortPercentOfFloat,0.0294
sharesShortPriorMonth,5480942
category,
fiveYearAverageReturn,
previousClose,78.19
regularMarketOpen,78.45
twoHundredDayAverage,72.75345
trailingAnnualDividendYield,
payoutRatio,0
volume24Hr,
regularMarketDayHigh,78.68
navPrice,
averageDailyVolume10Day,1591980
regularMarketPreviousClose,78.19
fiftyDayAverage,72.143
trailingAnnualDividendRate,
open,78.45
averageVolume10days,1591980
expireDate,
algorithm,
dividendRate,
exDividendDate,
circulatingSupply,
startDate,
regularMarketDayLow,77.86
currency,USD
trailingPE,32.529022
regularMarketVolume,1024872
lastMarket,
maxSupply,
openInterest,
marketCap,17331107840
volumeAllCurrencies,
strikePrice,
averageVolume,1804104
dayLow,77.86
ask,78.46
askSize,1000
volume,1024872
fiftyTwoWeekHigh,88.26
fromCurrency,
fiveYearAvgDividendYield,
fiftyTwoWeekLow,61.91
bid,78.46
tradeable,False
dividendYield,
bidSize,800
dayHigh,78.68
regularMarketPrice,78.46
preMarketPrice,
logo_url,https://logo.clearbit.com/incyte.com
